AFT Pharmaceuticals - FDA nod for opioid alternative, upside anticipated
AFT Pharmaceuticals announced FDA approval for Maxigesic IV, an intravenous form of its flagship pain relief prescription medicine. The FDA...
434 Views
AFT Pharmaceuticals - FDA Pain Is Over
AFT Pharmaceuticals (AFT) has finally received the long awaited US FDA approval for its Maxigesic IV product (hospital-based product)
354 Views
AFT Pharmaceuticals - AFTO judgment clears AFT of breach claim
AFT Pharmaceuticals has reported that the Auckland High Court has cleared it of the contractual breach claim filed by PBL Solutions in April 2020,...
455 Views
AFT Pharmaceuticals: FY23 Result — On Script
We liked what we saw in AFT Pharmaceuticals' (AFT) FY23 result: (1) ANZ revenue (AFT's core defensive growth driver) grew +24% versus FY22, (2)...
346 Views
AFT Pharmaceuticals (AFT): FY23 Result – First Impressions
AFT Pharmaceuticals (AFT) reported an operating FY23 result in-line with guidance and slightly ahead of our expectations with EBIT ex licensing...
339 Views